Predisposing factors, pathogenesis and therapeutic intervention of Kawasaki disease

Highlights • Kawasaki disease (KD) is an acute childhood disease with coronary artery lesions.• Endothelial cell injury is mediated by T cells and cytokines (TNF-α and IL-1β).• KD is due to an abnormal immunological response in genetically predisposed individuals.• Candidate KD susceptibility genes identified by GWAS include BLK, CD40 and FCGR2A.• Intravenous immunoglobulin and aspirin are the standard treatment of acute KD.• IVIG-resistant patients are treated with steroids, cyclosporine, anti-IL-1β or anti-TNF.

• Publication year

  2016

• Venue

  Drug Discovery Today

• Publication date

  2016-08-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.drudis.2016.08.004PMID 27506874PMCID 7185772
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• Intravenous immunoglobulin and aspirin are the standard treatment for acute Kawasaki disease, while IVIG-resistant patients receive steroids, cyclosporine, anti-IL-1β, or anti-TNF.

  Confidence 0.97

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewB (s683577b42) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewq (76h6bfydm6) reviewAK (4715169a40) reviewAnonymous (n259mg7uxy) review
• Kawasaki disease is framed as an abnormal immunological response in genetically predisposed individuals, with susceptibility genes identified by GWAS.

  Confidence 0.92

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewB (s683577b42) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewq (76h6bfydm6) reviewAK (4715169a40) reviewAnonymous (n259mg7uxy) review
• Endothelial cell injury in Kawasaki disease is mediated by T cells and cytokines including TNF-α and IL-1β.

  Confidence 0.96

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewB (s683577b42) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewq (76h6bfydm6) reviewAK (4715169a40) reviewAnonymous (n259mg7uxy) review
• Kawasaki disease is an acute childhood disease associated with coronary artery lesions.

  Confidence 0.98

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewB (s683577b42) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewq (76h6bfydm6) reviewAK (4715169a40) reviewAnonymous (n259mg7uxy) review

• aspirin

  treatments

  An anti-inflammatory and antiplatelet drug used in acute treatment of the disease.

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewB (s683577b42) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewq (76h6bfydm6) reviewAK (4715169a40) reviewAnonymous (n259mg7uxy) review
• candidate kd susceptibility genes

  gene sets

  Genetic loci proposed by genome-wide association studies as risk factors for the disease.

  Aliases: susceptibility genes

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewB (s683577b42) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewq (76h6bfydm6) reviewAK (4715169a40) reviewAnonymous (n259mg7uxy) review
• coronary artery lesions

  lesions

  Pathologic abnormalities of the coronary arteries associated with the disease.

  Aliases: CALs

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewB (s683577b42) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewq (76h6bfydm6) reviewAK (4715169a40) reviewAnonymous (n259mg7uxy) review
• cytokines

  molecules

  Immune signaling molecules implicated in the inflammatory response described in the review.

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewB (s683577b42) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewq (76h6bfydm6) reviewAK (4715169a40) reviewAnonymous (n259mg7uxy) review
• gwas

  research methods

  A genome-wide association approach used to identify disease susceptibility loci.

  Aliases: genome-wide association studies

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewB (s683577b42) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewq (76h6bfydm6) reviewAK (4715169a40) reviewAnonymous (n259mg7uxy) review
• il-1β

  molecules

  A pro-inflammatory cytokine mentioned as part of the endothelial injury mechanism and rescue therapy target.

  Aliases: interleukin-1 beta

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewB (s683577b42) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewq (76h6bfydm6) reviewAK (4715169a40) reviewAnonymous (n259mg7uxy) review
• intravenous immunoglobulin

  treatments

  An immunoglobulin therapy used in the acute management of the disease.

  Aliases: IVIG

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewB (s683577b42) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewq (76h6bfydm6) reviewAK (4715169a40) reviewAnonymous (n259mg7uxy) review
• ivig-resistant patients

  patient subgroups

  Patients whose disease does not respond adequately to intravenous immunoglobulin.

  Aliases: IVIG nonresponders

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewB (s683577b42) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewq (76h6bfydm6) reviewAK (4715169a40) reviewAnonymous (n259mg7uxy) review
• kawasaki disease

  conditions

  An acute childhood vasculitis discussed as the central disease entity in the review.

  Aliases: KD

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewB (s683577b42) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewq (76h6bfydm6) reviewAK (4715169a40) reviewAnonymous (n259mg7uxy) review
• t cells

  cell types

  Lymphocytes involved in immune-mediated vascular injury in the disease context.

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewB (s683577b42) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewq (76h6bfydm6) reviewAK (4715169a40) reviewAnonymous (n259mg7uxy) review
• tnf-α

  molecules

  A pro-inflammatory cytokine mentioned as part of the endothelial injury mechanism.

  Aliases: tumor necrosis factor alpha

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewB (s683577b42) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewq (76h6bfydm6) reviewAK (4715169a40) reviewAnonymous (n259mg7uxy) review

• Kawasaki disease in adults: Observations in France and literature review.

  2016cited by this paper
• Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).

  2016cited by this paper
• Genome-Wide Association Study Identifies Novel Susceptibility Genes Associated with Coronary Artery Aneurysm Formation in Kawasaki Disease

  2016cited by this paper
• Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin

  2016cited by this paper
• Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin

  2016cited by this paper
• Identification of an Association Between Genomic Hypomethylation of FCGR2A and Susceptibility to Kawasaki Disease and Intravenous Immunoglobulin Resistance by DNA Methylation Array

  2015cited by this paper
• Molecular and immunological biomarkers to predict IVIg response.

  2015cited by this paper
• The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease

  2015cited by this paper
• A Common Immunopathogenesis Mechanism for Infectious Diseases: The Protein-Homeostasis-System Hypothesis

  2015cited by this paper
• IL-1 Signaling Is Critically Required in Stromal Cells in Kawasaki Disease Vasculitis Mouse Model: Role of Both IL-1&agr; and IL-1&bgr;

  2015cited by this paper
• Inhibitory Effect of Statins on Inflammation-Related Pathways in Human Abdominal Aortic Aneurysm Tissue

  2015cited by this paper
• A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

  2015cited by this paper
• Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis

  2015cited by this paper
• Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs

  2015cited by this paper
• Th17‐ and Treg‐related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease

  2015cited by this paper
• Descriptive epidemiology of Kawasaki disease in Japan, 2011-2012: from the results of the 22nd nationwide survey.

  2015cited by this paper
• Kawasaki disease: an evolving paradigm.

  2015cited by this paper
• Management of Kawasaki Disease in Resource-limited Settings

  2015cited by this paper
• Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients

  2014cited by this paper
• Effect of Gymnema sylvestre on pharmacokinetics and pharmacodynamics of Pioglitazone in diabetic rats

  2014cited by this paper
• Epidemiologic Features of Kawasaki Disease in South Korea: Data from Nationwide Survey, 2009–2011

  2014cited by this paper
• Viral infections associated with Kawasaki disease

  2014cited by this paper
• Downregulation of Th17 cells and the related cytokines with treatment in Kawasaki disease.

  2014cited by this paper
• Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation

  2014cited by this paper
• Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin

  2014cited by this paper
• Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.

  2014cited by this paper
• Single-Nucleotide Polymorphism rs7251246 in ITPKC Is Associated with Susceptibility and Coronary Artery Lesions in Kawasaki Disease

  2014cited by this paper
• High dose anakinra for treatment of severe neonatal Kawasaki disease: a case report

  2014cited by this paper
• Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain–Barré syndrome patients

  2014cited by this paper
• Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

  2013cited by this paper
• Seasonality of Kawasaki Disease: A Global Perspective

  2013cited by this paper
• Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.

  2013influential reference
• Management of Kawasaki disease

  2013cited by this paper
• Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells.

  2013cited by this paper
• Intravenous Gammaglobulin Inhibits Encephalitogenic Potential of Pathogenic T Cells and Interferes with their Trafficking to the Central Nervous System, Implicating Sphingosine-1 Phosphate Receptor 1–Mammalian Target of Rapamycin Axis

  2013cited by this paper
• Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.

  2012cited by this paper
• Epidemiology of Kawasaki Disease in Asia, Europe, and the United States

  2012cited by this paper
• Three Linked Vasculopathic Processes Characterize Kawasaki Disease: A Light and Transmission Electron Microscopic Study

  2012cited by this paper
• Interleukin-1&bgr; Is Crucial for the Induction of Coronary Artery Inflammation in a Mouse Model of Kawasaki Disease

  2012cited by this paper
• Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease.

  2012influential reference
• Augmented TLR2 Expression on Monocytes in both Human Kawasaki Disease and a Mouse Model of Coronary Arteritis

  2012cited by this paper
• Marked Acceleration of Atherosclerosis After Lactobacillus casei–Induced Coronary Arteritis in a Mouse Model of Kawasaki Disease

  2012cited by this paper
• A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation

  2012cited by this paper
• Corticosteroid Pulse Combination Therapy for Refractory Kawasaki Disease: A Randomized Trial

  2012cited by this paper
• Long‐term efficacy of plasma exchange treatment for refractory Kawasaki disease

  2012cited by this paper
• Genetics of Kawasaki disease: what we know and don't know.

  2012cited by this paper
• Intravenous Immunoglobulin Expands Regulatory T Cells in Autoimmune Rheumatic Disease

  2012cited by this paper
• Inflammatory cytokine profiles during Cyclosporin treatment for immunoglobulin-resistant Kawasaki disease.

  2012cited by this paper
• Efficacy and Limitation of Infliximab Treatment for Children with Kawasaki Disease Intractable to Intravenous Immunoglobulin Therapy: Report of an Open-label Case Series

  2012cited by this paper
• A genome-wide association study identifies three new risk loci for Kawasaki disease

  2012cited by this paper
• Two new susceptibility loci for Kawasaki disease identified through genome-wide association analysis

  2012cited by this paper
• Comparison of different IVIg preparations on IL-17 production by human Th17 cells.

  2011cited by this paper
• Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a "new" virus associated with Kawasaki disease.

  2011cited by this paper
• Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.

  2011cited by this paper
• CASP3 gene single-nucleotide polymorphism (rs72689236) and Kawasaki disease in Taiwanese children

  2011cited by this paper
• Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance.

  2011cited by this paper
• The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders.

  2011cited by this paper
• Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients.

  2011cited by this paper
• Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease

  2011cited by this paper
• Transforming growth factor-beta signaling pathway in patients with Kawasaki disease.

  2011cited by this paper
• Cyclosporin A Treatment for Kawasaki Disease Refractory to Initial and Additional Intravenous Immunoglobulin

  2011cited by this paper
• The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease

  2010cited by this paper
• Common variants in CASP3 confer susceptibility to Kawasaki disease.

  2010cited by this paper
• Kawasaki disease: Aetiopathogenesis and therapeutic utility of intravenous immunoglobulin

  2009cited by this paper
• Infliximab Treatment of Intravenous Immunoglobulin–Resistant Kawasaki Disease

  2009cited by this paper
• Epidemiologic Features of Kawasaki Disease in Taiwan, 2003–2006

  2009cited by this paper
• Increased nitric oxide production by neutrophils in early stage of Kawasaki disease

  2009cited by this paper
• The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.

  2009cited by this paper
• Modulation of the cellular immune system by intravenous immunoglobulin.

  2008cited by this paper
• Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.

  2008cited by this paper
• ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms

  2008cited by this paper
• What is the contents of the magic draft IVIg?

  2008cited by this paper
• Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin

  2008cited by this paper
• Low-dose Methotrexate Therapy for Intravenous Immunoglobulin-resistant Kawasaki Disease

  2008cited by this paper
• Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease

  2007cited by this paper
• (S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme/Caspase-1 Inhibitor, Exhibits Potent Anti-Inflammatory Act

  2007cited by this paper
• Kawasaki disease may be a hyperimmune reaction of genetically susceptible children to variants of normal environmental flora

  2007cited by this paper
• Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive Function

  2007cited by this paper
• Gene Expression Profiling of the Effect of High-Dose Intravenous Ig in Patients with Kawasaki Disease1

  2005cited by this paper
• Intravenous immunoglobulin does not increase FcγRIIB expression on monocytes/macrophages during acute Kawasaki disease

  2005cited by this paper
• Cytoplasmic Inclusion Bodies Are Detected by Synthetic Antibody in Ciliated Bronchial Epithelium during Acute Kawasaki Disease

  2005cited by this paper
• Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease.

  2005cited by this paper
• Presentations at the annual spring meeting of The Danish Society for Rheumatology, Rungstedgaard, April 29–30, 2005

  2005cited by this paper
• Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate.

  2005cited by this paper
• Intravenous immunoglobulin inhibits NF-κB activation and affects Fcγ receptor expression in monocytes/macrophages

  2004cited by this paper
• Intravenous immunoglobulin inhibits NF-kappaB activation and affects Fcgamma receptor expression in monocytes/macrophages.

  2004cited by this paper
• Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin

  2004influential reference
• Epidemiologic Features of Kawasaki Disease in Taiwan, 1996–2002

  2004cited by this paper
• Salicylate for the treatment of Kawasaki disease in children.

  2003cited by this paper
• The role of anti‐endothelial cell antibodies in Kawasaki disease –in vitro and in vivo studies

  2002cited by this paper
• Maternal antibody against toxic shock syndrome toxin-1 may protect infants younger than 6 months of age from developing Kawasaki syndrome.

  2002cited by this paper
• Cytokine Modulation with Immune γ-Globulin in Peripheral Blood of Normal Children and Its Implications in Kawasaki Disease Treatment

  2001cited by this paper
• Re‐treatment for immune globulin‐resistant Kawasaki disease: A comparative study of additional immune globulin and steroid pulse therapy

  2001cited by this paper
• Superantigens, conventional antigens and the etiology of Kawasaki syndrome.

  2000cited by this paper
• Initial intravenous gammaglobulin treatment failure in Kawasaki disease.

  2000cited by this paper
• IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease.

  2000cited by this paper
• Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose.

  1997cited by this paper
• Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki disease.

  1992cited by this paper
• A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome.

  1991cited by this paper
• Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease.

  1989cited by this paper

• Analysis of risk factors of coronary artery lesions in Kawasaki disease and study of IVIG treatment response

  2026cites this paper
• Updates in the Treatment of Kawasaki Disease

  2025cites this paper
• Correlation between peripheral blood Th17/Treg immune imbalance and coronary artery lesions in children with Kawasaki disease

  2025cites this paper
• Predictive value of novel nutritional inflammation indexes in IVIG-unresponsive Kawasaki disease: a retrospective study

  2025cites this paper
• Ergodic property and density function of a stochastic Kawasaki disease model

  2025cites this paper
• Association between C-reactive protein–albumin–lymphocyte (CALLY) index with intravenous immunoglobulin non-response in Kawasaki disease

  2025cites this paper
• C-reactive protein to albumin ratio as a prognostic tool for predicting intravenous immunoglobulin resistance in children with kawasaki disease: a systematic review of cohort studies

  2024cites this paper
• Neurological and immunological adverse events after pneumococcal conjugate vaccine in children using national immunization programme registry data.

  2024cites this paper
• Plasma Cyclooxygenase-2 as a Potential Biomarker for Early Diagnosis of Kawasaki Disease

  2023cites this paper
• Kawasaki disease in Malaysia: Biochemical profile, characterization, diagnosis and treatment

  2023cites this paper
• Values of prognostic nutritional index for predicting Kawasaki disease: a systematic review and meta-analysis

  2023cites this paper
• Nomogram for predicting coronary artery lesions in patients with Kawasaki disease

  2023cites this paper
• Multisystem Inflammatory Syndrome in Children

  2022cites this paper
• Tenascin-C predicts IVIG non-responsiveness and coronary artery lesions in kawasaki disease in a Chinese cohort

  2022cites this paper
• COVID-19 Infection: The Virus and Its Origin, the Variants, the Immune Defense, the Multiorgan Autoimmune Reactions, and the Targeted Treatments

  2022cites this paper
• Value of blood inflammatory markers for predicting intravenous immunoglobulin resistance in Kawasaki disease: A systematic review and meta-analysis

  2022cites this paper
• Establishment and Validation of a Multivariate Predictive Scoring Model for Intravenous Immunoglobulin-Resistant Kawasaki Disease: A Study of Children From Two Centers in China

  2022cites this paper
• Ultrasound evaluation of endothelial dysfunction in immunoglobulin-resistant children with acute Kawasaki disease

  2022cites this paper
• Neonatal sepsis and Kawasaki disease

  2022cites this paper
• Autoantibodies and autoimmune disorders in SARS-CoV-2 infection: pathogenicity and immune regulation

  2022cites this paper
• Efficacy of Gamma Globulins in Children with Kawasaki Disease and Factors Influencing Children's Short-Term Prognosis

  2022cites this paper
• Роль иммунной системы в развитии и прогрессировании вирусного повреждения миокарда

  2021cites this paper
• Kawasaki Disease: Predictors of Resistance to Intravenous Immunoglobulin and Cardiac Complications.

  2021cites this paper
• In silico Identification of 10 Hub Genes and an miRNA–mRNA Regulatory Network in Acute Kawasaki Disease

  2021cites this paper
• Predictive value of brachial artery flow-mediated dilation on coronary artery abnormality in acute stage of Kawasaki disease

  2021cites this paper
• Recombinant Human Soluble Thrombomodulin Suppresses Arteritis in a Mouse Model of Kawasaki Disease

  2021cites this paper
• Boolean analysis of the transcriptomic data to identify novel biomarkers of IVIG response.

  2021cites this paper
• Combined Single Nucleotide Variants of ORAI1 and BLK in a Child with Refractory Kawasaki Disease

  2021cites this paper
• Global dynamics analysis of a time-delayed dynamic model of Kawasaki disease pathogenesis

  2021cites this paper
• Differential expression of long non-coding RNAs SRA, HCG22 and MHRT in children with Kawasaki disease.

  2021cites this paper
• Permanence and extinction for a nonautonomous Kawasaki disease model with time delays

  2021cites this paper
• Preterm birth and Kawasaki disease: a nationwide Japanese population-based study

  2021influential citation
• Immune system in development and progression of viral myocardial damage

  2021cites this paper
• Doença de Kawasaki: Preditores de Resistência à Imunoglobulina Intravenosa e Complicações Cardíacas

  2020cites this paper
• Autoimmune and inflammatory diseases following COVID-19

  2020cites this paper
• Neutrophil-to-lymphocyte ratio as a biomarker for predicting the intravenous immunoglobulin-resistant Kawasaki disease

  2020cites this paper
• The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence, mechanisms and therapeutic modalities

  2020cites this paper
• Efficacy of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis

  2020cites this paper
• Effects of changes on gut microbiota in children with acute Kawasaki disease

  2020cites this paper
• The IL-1B Gene Polymorphisms rs16944 and rs1143627 Contribute to an Increased Risk of Coronary Artery Lesions in Southern Chinese Children with Kawasaki Disease

  2019cites this paper
• Leveraging Genetic Findings for Precision Medicine in Vasculitis

  2019cites this paper
• Serum Levels of Syndecan-1 in Patients With Kawasaki Disease

  2018cites this paper
• Maladie de Kawasaki

  2018cites this paper
• Adeno-associated Virus Vector-mediated Interleukin-10 Induction Prevents Vascular Inflammation in a Murine Model of Kawasaki Disease

  2018cites this paper
• Treatment Options for Resistant Kawasaki Disease

  2018cites this paper
• Cognitive Development After Kawasaki Disease　- Clinical Study and Validation Using a Nationwide Population-Based Cohort.

  2017cites this paper
• Relationship between IL-27 and coronary arterial lesions in children with Kawasaki disease

  2017cites this paper
• A comparison of the predictive validity of the combination of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and other risk scoring systems for intravenous immunoglobulin (ivig)-resistance in Kawasaki disease

  2017cites this paper
• IVIG-mediated effector functions in autoimmune and inflammatory diseases

  2017cites this paper
• IL-1 Inhibition May Have an Important Role in Treating Refractory Kawasaki Disease

  2017cites this paper